Patents by Inventor Erica A. Golemis

Erica A. Golemis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080118919
    Abstract: A combined yeast/bacterial two-hybrid system is disclosed.
    Type: Application
    Filed: August 31, 2005
    Publication date: May 22, 2008
    Applicant: FOX CHASE CANCER CENTER
    Inventors: Ilya G. Serebriiskii, Erica A. Golemis, J. Keith Joung
  • Publication number: 20060264473
    Abstract: Isoindolone derivatives, compositions containing the same, and methods of use thereof for the treatment or prophylaxis of viral infection are disclosed.
    Type: Application
    Filed: April 27, 2006
    Publication date: November 23, 2006
    Inventors: Vladimir Khazak, Erica Golemis, Sanjay Menon, Lutz Weber
  • Patent number: 6653074
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein, HEF-1, involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents in methods for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: November 25, 2003
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Geraldine O'Neill, Sarah Fashena
  • Publication number: 20030211495
    Abstract: The present invention relates provides an improved reverse n-hybrid screening method for identifying antagonists or inhibitors of biological interactions, wherein multiple reporter genes are employed to distinguish antagonists or inhibitors of one interaction from those antagonists or inhibitors of other interactions, particularly where each of said interactions involves one or more common interacting partners. A further aspect of the invention provides novel expression vectors for performing the inventive method, particularly in high throughput screens.
    Type: Application
    Filed: January 14, 2003
    Publication date: November 13, 2003
    Inventors: Richard Hopkins, Ilya Serebriiskii, Paul Michael Watt, Erica Golemis
  • Patent number: 6326150
    Abstract: The present invention provides an improved yeast interaction trap method and reagents for the detection of novel protein-protein interactions. The invention comprises a dual bait system which improves the accuracy of library screens with an immediate selection to eliminate false positives. The dual bait system of the present invention also allows for comparative, simultaneous assessment of interactions between two related members of a protein family or a wild-type versus mutated form of the same protein.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: December 4, 2001
    Assignee: Fox Chase Cancer Center
    Inventors: Erica Golemis, Ilya Serebriiskii, Vladimir Khazak
  • Patent number: 6124434
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an Internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: September 26, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Susan F. Law, Joanne Estojak
  • Patent number: 6100384
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: August 8, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Susan F. Law, Joanne Estojak
  • Patent number: 5786169
    Abstract: Disclosed is a method for determining whether a first protein is capable of physically interacting with a second protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a weak gene activating moiety; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Such a determination facilitates the isolation of the gene encoding the interacting protein. Also disclosed herein is recombinant Cdi1 polypeptide, nucleic acid encoding the Cdi1 polypeptide, and uses thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 28, 1998
    Assignee: The General Hospital Corporation
    Inventors: Roger Brent, Jeno Gyuris, Erica Golemis
  • Patent number: 5770717
    Abstract: An isolated nucleic acid is provided, which encodes a stress-responsive subunit of mammalian RNA polymerase II, RPB4. In a preferred embodiment, the human RPB4 subunit (hsRPB4) is provided. Also provided are oligonucleotides that specifically hybridize with the nucleic acid, the purified polypeptide encoded by the nucleic acid and antibodies immunologically specific for the polypeptide. These biological molecules are useful as markers of stress-related responses, which may correspond to the occurrence of malignant disease, and as therapeutic agents to modify resistance of a selected cell population to external stress conditions, such as that resulting from treatment of a patient with chemotherapeutic agents.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: June 23, 1998
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Vladimir Khazak, Joanne Estojak
  • Patent number: 5716782
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: June 30, 1995
    Date of Patent: February 10, 1998
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Susan F. Law, Joanne Estojak
  • Patent number: 5580721
    Abstract: A method for the identification of compounds as inhibitors of oncoprotein action is described. A compound is identified as an inhibitor of oncoprotein action based on its ability to modulate the transcription of a reporter gene. Transcription of the reporter gene is dependent upon the binding of a fusion oncoprotein to a specific DNA binding element positioned upstream of the reporter gene promoter. The fusion oncoprotein contains a transcriptional regulatory domain from an oncoprotein and a DNA binding domain from a different protein.
    Type: Grant
    Filed: October 7, 1993
    Date of Patent: December 3, 1996
    Assignee: The General Hospital Corporation
    Inventors: Roger Brent, Erica Golemis, Karen F. Lech, Catherine Anderson
  • Patent number: 5580736
    Abstract: Disclosed is a method for determining whether a first protein is capable of physically interacting with a second protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a weak gene activating moiety; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Such a determination facilitates the isolation of the gene encoding the interacting protein. Also disclosed herein is recombinant Cdi1 polypeptide, nucleic acid encoding the Cdi1 polypeptide, and uses thereof.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: December 3, 1996
    Assignee: The General Hospital Corporation
    Inventors: Roger Brent, Jeno Gyuris, Erica Golemis